As such, blockade of targets such as SHP2 may have particular efficacy with an oncogenic overexpression of WT KRAS protein relative to a tumor with a mutant KRAS protein whose cycling between active and inactive forms is dysregulated. The gene discussed is KRAS; the disease is neoplasm.